Dirk Arnold, MD, PhD; Tanios Bekaii-Saab, MD; Fortunato Ciardiello, MD, PhD; Paul R. Helft, MD; and John L. Marshall, MD, discuss the roles of anti-vascular endothelial growth factor therapy and anti-epidermal growth factor receptor therapy in the second-line metastatic colorectal cancer setting, and the rationale for treating beyond progression.
